Fig. 8

Cells exhibiting elevated levels of TMPRSS2 demonstrated increased levels of PD-L1, the IFN pathway, HLA class I antigen presentation machinery (APM) and immune responses in comparison to those with lower TMPRSS2 levels. This indicates that the expression of TMPRSS2 across various model systems and following SARS-CoV-2 infection correlates with alterations in host immunogenicity. These alterations may influence the efficacy of the PD-1 inhibitor nivolumab, which enhances the migration of immune cells and decreases cytokines associated with innate immunity (created with BioRender.com)